Opinion

Video

Benefits of Incorporating Fusion-Guided Biopsy into Practice

Author(s):

David I. Lee, MD, FACS,Firas F. Abdollah, MD

Firas F. Abdollah, MD, provides insights on how MRI- or fusion-guided technologies are used with transrectal and transperineal biopsy procedures and how they improve traditional biopsy procedures.

Related Videos
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Ruben Olivares, MD, answers a question during a Zoom video interview
Doctor consulting patient | Image Credit: © Liudmila Dutko - stock.adobe.com
Stacy Loeb, MD, MSc, PhD (Hon), answers a question during a Zoom video interview
1 expert in this video
1 expert in this video
Related Content
Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer
June 17th 2025

Study to evaluate impact of ArteraAI on clinical decision-making for prostate cancer

Hannah Clarke
ArteraAI is a multimodal artificial intelligence biomarker test that can predict therapy benefit and prognosticate long-term outcomes in prostate cancer.
Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
April 27th 2025

Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
AI-based tool aims to optimize MRI use in prostate cancer diagnosis
June 12th 2025

AI-based tool aims to optimize MRI use in prostate cancer diagnosis

Madhur Nayan, MD, PhD
"I'm excited to see how these models are going to continue to be developed and applied in clinical practice, because precision medicine is here, and I’m looking forward to it," says Madhur Nayan, MD, PhD.
Dr. Murphy on increasing diversity in cancer clinical trials
February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff
In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer
June 11th 2025

Adding cetrelimab to niraparib maintenance shows benefit in aggressive variant prostate cancer

Hannah Clarke
However, this regimen was associated with substantial toxicity, so careful patient selection is paramount, according to the authors.
Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC
June 9th 2025

Phase 1 study launches for novel CYP11A1 inhibitor for mCRPC

Hannah Clarke
In preclinical studies, ACE-232 demonstrated superior potency, efficacy, and pharmacokinetic properties compared with other CYP11A1 inhibitors.
© 2025 MJH Life Sciences

All rights reserved.